Polycystic ovary syndrome: etiology, pathogenesis and diagnosis

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age, with a prevalence of up to 10%. Various diagnostic criteria have been proposed, generally centered around the features of hyperandrogenism and/or hyperandrogenemia, oligo-ovulation and polycystic ovarian morphology. Insulin resistance is present in a majority of cases, with compensatory hyperinsulinemia contributing to hyperandrogenism via stimulation of ovarian androgen secretion and inhibition of hepatic sex hormone-binding globulin production. Adipose tissue dysfunction has been implicated as a contributor to the insulin resistance observed in PCOS. Environmental and genetic factors also have a role in the development of PCOS. The syndrome is associated with numerous morbidities, including infertility, obstetrical complications, type 2 diabetes mellitus, cardiovascular disease, and mood and eating disorders. Despite these morbidities, PCOS may be common in our society owing to evolutionary advantages of the syndrome in ancient times, including smaller family sizes, reduced exposure to childbirth-related mortality, increased muscle mass and greater capacity to store energy. The diagnosis of PCOS hinges on establishing key features while ruling out other hyperandrogenic or oligo-ovulatory disorders. Treatment is focused on the goals of ameliorating hyperandrogenic symptoms, inducing ovulation and preventing cardiometabolic complications.

[1]  J. Dungan Molecular Abnormalities in Oocytes from Women with Polycystic Ovary Syndrome Revealed by Microarray Analysis , 2008 .

[2]  M. Hull Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. , 1987, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[3]  F. Manguso,et al.  Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. , 2007, Human reproduction.

[4]  E. Diamanti-Kandarakis,et al.  Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). , 2001, American journal of physiology. Endocrinology and metabolism.

[5]  O. Ortmann,et al.  Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients. , 1999, Human reproduction.

[6]  M. Davies,et al.  Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. , 2001, Human reproduction.

[7]  J. Goldberg,et al.  Screening for bipolar disorder in women with polycystic ovary syndrome: a pilot study. , 2006, Journal of affective disorders.

[8]  G. Conway,et al.  Polycystic ovary syndrome : a guide to clinical management , 2005 .

[9]  S. Whitehead,et al.  Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. , 2007, The Journal of clinical endocrinology and metabolism.

[10]  G. Azevedo,et al.  [Menstrual cycle irregularity as a marker of cardiovascular risk factors at postmenopausal years]. , 2006, Arquivos brasileiros de endocrinologia e metabologia.

[11]  M. Byrne,et al.  Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. , 1995, The Journal of clinical investigation.

[12]  Ana M Soto,et al.  Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. , 2009, Endocrine reviews.

[13]  R. Azziz,et al.  Androgen excess disorders in women , 2007 .

[14]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[15]  W. Wiser,et al.  Hyperthecosis: an inheritable form of polycystic ovarian disease. , 1975, Birth defects original article series.

[16]  M. Hickey,et al.  The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study. , 2009, The Journal of clinical endocrinology and metabolism.

[17]  E. Diamanti-Kandarakis,et al.  Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. , 2010, European journal of endocrinology.

[18]  T. Lesnick,et al.  Insulin and messenger ribonucleic acid expression of insulin receptor isoforms in ovarian follicles from nonhirsute ovulatory women and polycystic ovary syndrome patients. , 2004, The Journal of clinical endocrinology and metabolism.

[19]  T. Lesnick,et al.  Follicle luteinization in hyperandrogenic follicles of polycystic ovary syndrome patients undergoing gonadotropin therapy for in vitro fertilization. , 2006, The Journal of clinical endocrinology and metabolism.

[20]  E. Carmina,et al.  Correlates of increased lean muscle mass in women with polycystic ovary syndrome. , 2009, European journal of endocrinology.

[21]  S. Bhattacharya,et al.  Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. , 2009, Reproductive biomedicine online.

[22]  K. Højlund,et al.  Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. , 2008, The Journal of clinical endocrinology and metabolism.

[23]  R. Azziz The evaluation and management of hirsutism. , 2003, Obstetrics and gynecology.

[24]  A. López-Bermejo,et al.  Low body adiposity and high leptinemia in breast-fed infants born small-for-gestational-age. , 2010, The Journal of pediatrics.

[25]  E. Talbott,et al.  Risk of T2DM and impaired fasting glucose among pcos subjects: Results of an 8-year follow-up , 2006, Current diabetes reports.

[26]  H. Mason,et al.  Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid. , 1994, The Journal of clinical endocrinology and metabolism.

[27]  J. Marshall,et al.  Regulation of Gonadotropin Secretion: Implications for Polycystic Ovary Syndrome , 2002, Seminars in reproductive medicine.

[28]  I. Stein,et al.  Amenorrhea associated with bilateral polycystic ovaries , 1935 .

[29]  P. Lavori,et al.  Valproate Is Associated with New-Onset Oligoamenorrhea with Hyperandrogenism in Women with Bipolar Disorder , 2006, Biological Psychiatry.

[30]  M. McCarthy,et al.  Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. , 2004, The Journal of clinical endocrinology and metabolism.

[31]  M. Goodarzi,et al.  Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 6 17beta-hydroxysteroid dehydrogenase gene. , 2009, The Journal of clinical endocrinology and metabolism.

[32]  R. Steegers-Theunissen,et al.  A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. , 2008, The Journal of clinical endocrinology and metabolism.

[33]  R. Lobo,et al.  Isolated polycystic morphology in ovum donors predicts response to ovarian stimulation. , 1995, Human reproduction.

[34]  K. Segal,et al.  Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome , 1989, Diabetes.

[35]  S. Emans,et al.  Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. , 2002, The Journal of clinical endocrinology and metabolism.

[36]  A Sekikawa,et al.  Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. , 1999, Diabetes care.

[37]  P. Magnus,et al.  Familial clustering in the polycystic ovarian syndrome. , 1989, Gynecologic and obstetric investigation.

[38]  R. Casper,et al.  Review: aromatase inhibitors for ovulation induction. , 2006, The Journal of clinical endocrinology and metabolism.

[39]  John A. Barry,et al.  Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels , 2010, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[40]  E. Codner,et al.  Increased anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. , 2006, The Journal of clinical endocrinology and metabolism.

[41]  A. González-Bulnes Novel concepts in ovarian endocrinology. , 2007 .

[42]  R. Norman,et al.  Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. , 2006, The Journal of clinical endocrinology and metabolism.

[43]  S. Nussey,et al.  Insulin resistance and endothelial dysfunction in the brothers of Indian subcontinent Asian women with polycystic ovaries , 2004, Clinical endocrinology.

[44]  M. Eijkemans,et al.  A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. , 2006, Human reproduction update.

[45]  W. Crowley,et al.  Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. , 1988, The Journal of clinical endocrinology and metabolism.

[46]  Thessaloniki,et al.  Consensus on infertility treatment related to polycystic ovary syndrome. , 2008, Fertility and sterility.

[47]  L. Liao,et al.  Effect of bisphenol A on steroid hormone production in rat ovarian theca-interstitial and granulosa cells , 2008, Molecular and Cellular Endocrinology.

[48]  J. Supko,et al.  Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome. , 2007, The Journal of clinical endocrinology and metabolism.

[49]  S. Elsenbruch,et al.  Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome , 2008, Brain, Behavior, and Immunity.

[50]  F. de Zegher,et al.  Early Origins of polycystic ovary syndrome: hypotheses may change without notice. , 2009, The Journal of clinical endocrinology and metabolism.

[51]  A. Lucky,et al.  Dysregulation of cytochrome P450c17α as the cause of polycystic ovarian syndrome , 1990 .

[52]  R. Azziz,et al.  Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. , 1998, Fertility and sterility.

[53]  E. Wickham,et al.  Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society. , 2007, The Journal of clinical endocrinology and metabolism.

[54]  L. Moran,et al.  Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. , 2009, Human reproduction update.

[55]  Lee-wen Huang,et al.  IVF versus ICSI in sibling oocytes from patients with polycystic ovarian syndrome: a randomized controlled trial. , 2005, Human reproduction.

[56]  J. Nestler,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(4):1929–1935 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-1045 Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycysti , 2022 .

[57]  A. Dokras,et al.  Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. , 2009, Fertility and sterility.

[58]  A. Vidal-Puig,et al.  It's Not How Fat You Are, It's What You Do with It That Counts , 2008, PLoS biology.

[59]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[60]  F. Schmidt Meta-Analysis , 2008 .

[61]  M. Cavaghan,et al.  Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. , 1999, Diabetes care.

[62]  T. Arora,et al.  Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. , 2000, The Journal of clinical endocrinology and metabolism.

[63]  Y. Taketani,et al.  Gender difference in serum bisphenol A levels may be caused by liver UDP-glucuronosyltransferase activity in rats. , 2004, Biochemical and biophysical research communications.

[64]  Judith R. Rager,et al.  Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. , 2004, The Journal of clinical endocrinology and metabolism.

[65]  R. Norman,et al.  Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. , 2010, The Journal of clinical endocrinology and metabolism.

[66]  R. Cífková,et al.  Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. , 2000, Human reproduction.

[67]  S. Reis,et al.  The Economic Burden of Angina in Women With Suspected Ischemic Heart Disease: Results From the National Institutes of Health–National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation , 2006, Circulation.

[68]  R. Azziz,et al.  Visually scoring hirsutism. , 2010, Human reproduction update.

[69]  W. Dodson,et al.  Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. , 1999, The Journal of clinical endocrinology and metabolism.

[70]  S. Mudaliar,et al.  Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. , 2009, The Journal of clinical endocrinology and metabolism.

[71]  S. Reis,et al.  Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. , 2008, The Journal of clinical endocrinology and metabolism.

[72]  S. Reeders,et al.  FAMILIAL POLYCYSTIC OVARIES: A GENETIC DISEASE? , 1988, Clinical endocrinology.

[73]  H. Mason,et al.  Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. , 1996, The Journal of clinical endocrinology and metabolism.

[74]  M. Goodarzi,et al.  Polycystic ovary syndrome: an ancient disorder? , 2011, Fertility and sterility.

[75]  S. Necozione,et al.  Low birth weight and later development of insulin resistance and biochemical/clinical features of polycystic ovary syndrome. , 2008, Metabolism: clinical and experimental.

[76]  G. Rini,et al.  Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. , 2009, Fertility and sterility.

[77]  P. G. Knight,et al.  Local roles of TGF-beta superfamily members in the control of ovarian follicle development. , 2003, Animal reproduction science.

[78]  M. Goodarzi,et al.  Nonreplication of the type 5 17beta-hydroxysteroid dehydrogenase gene association with polycystic ovary syndrome. , 2008, The Journal of clinical endocrinology and metabolism.

[79]  anonymous,et al.  Comprehensive review , 2019 .

[80]  R. Azziz,et al.  Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. , 2001, Fertility and sterility.

[81]  K. Taylor,et al.  Androgen excess in women: experience with over 1000 consecutive patients. , 2004, The Journal of clinical endocrinology and metabolism.

[82]  J. Suls,et al.  Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis , 2009, Psychosomatic medicine.

[83]  E. Codner,et al.  Anti-Müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. , 2007, The Journal of clinical endocrinology and metabolism.

[84]  M. McCarthy,et al.  Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms , 2003, International Journal of Obesity.

[85]  Y. Taketani,et al.  Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. , 2004, Endocrine journal.

[86]  R. Wild Long-term health consequences of PCOS. , 2002, Human reproduction update.

[87]  R. Azziz,et al.  Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor-{alpha}. , 2010, The Journal of clinical endocrinology and metabolism.

[88]  J. Marshall,et al.  The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. , 2006, Human reproduction update.

[89]  B. Bavister,et al.  A macaque model for studying mechanisms controlling oocyte development and maturation in human and non-human primates. , 1999, Human reproduction.

[90]  D. Dewailly,et al.  Ultrasound examination of polycystic ovaries: is it worth counting the follicles? , 2003, Human reproduction.

[91]  Ravinder J. Singh,et al.  Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels. , 2010, The Journal of clinical endocrinology and metabolism.

[92]  M. Sauer,et al.  Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing. , 2000, The Journal of clinical endocrinology and metabolism.

[93]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[94]  B. Urman,et al.  The outcome of in vitro fertilization and embryo transfer in women with polycystic ovary syndrome failing to conceive after ovulation induction with exogenous gonadotropins. , 1992, Fertility and sterility.

[95]  A. Gadducci,et al.  Polycystic ovary syndrome and gynecological cancers: Is there a link? , 2005, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[96]  V. Padmanabhan,et al.  Polycystic ovary syndrome and its developmental origins , 2007, Reviews in Endocrine and Metabolic Disorders.

[97]  R. Casper,et al.  Aromatase Inhibitors for Ovulation Induction , 2006 .

[98]  L. Kuller,et al.  Evidence for Association Between Polycystic Ovary Syndrome and Premature Carotid Atherosclerosis in Middle-Aged Women , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[99]  B. Grubb,et al.  Clinical signs of androgen excess as risk factors for coronary artery disease. , 1990, Fertility and sterility.

[100]  J. Wood,et al.  Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis. , 2007, The Journal of clinical endocrinology and metabolism.

[101]  M. Primeau,et al.  Androgens and Mood Dysfunction in Women: Comparison of Women With Polycystic Ovarian Syndrome to Healthy Controls , 2004, Psychosomatic medicine.

[102]  J. L. San Millán,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from Spain* , 1999 .

[103]  M. Eijkemans,et al.  PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO‐II anovulation and association with metabolic factors , 2006, BJOG : an international journal of obstetrics and gynaecology.

[104]  L. Moran,et al.  Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. , 2009, Fertility and sterility.

[105]  Rita Ouellet-Hellstrom,et al.  Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. , 2010, JAMA.

[106]  R. Pasquali,et al.  Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. , 1989, The Journal of clinical endocrinology and metabolism.

[107]  E. Codner,et al.  Birth weight in offspring of mothers with polycystic ovarian syndrome. , 2005, Human reproduction.

[108]  G. Guyatt,et al.  Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. , 2004, Journal of clinical epidemiology.

[109]  Janet E Hall,et al.  Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. , 2006, The Journal of clinical endocrinology and metabolism.

[110]  M. Rizzo,et al.  Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? , 2005, Journal of atherosclerosis and thrombosis.

[111]  R. Norman,et al.  Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. , 1999, The Journal of clinical endocrinology and metabolism.

[112]  R. Azziz,et al.  Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome. , 2009, The Journal of clinical endocrinology and metabolism.

[113]  A. Corbould Insulin resistance in skeletal muscle and adipose tissue in polycystic ovary syndrome: are the molecular mechanisms distinct from type 2 diabetes? , 2008, Panminerva medica.

[114]  V. Hiilesmaa,et al.  Obstetric outcome in women with polycystic ovarian syndrome. , 2001, Human reproduction.

[115]  R. Norman,et al.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. , 2009, Fertility and sterility.

[116]  T. Suppes,et al.  Reproductive function and risk for PCOS in women treated for bipolar disorder. , 2005, Bipolar disorders.

[117]  C. Berne,et al.  Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. , 1994, The Journal of clinical endocrinology and metabolism.

[118]  M. McCarthy,et al.  Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits. , 2005, The Journal of clinical endocrinology and metabolism.

[119]  H. Bettiol,et al.  High prevalence of polycystic ovary syndrome in women born small for gestational age. , 2010, Human reproduction.

[120]  S. Weitsman,et al.  5α-Reductase Activity in Women with Polycystic Ovary Syndrome1 , 1999 .

[121]  Ricardo Azziz,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(6):2745–2749 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-032046 The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected , 2022 .

[122]  M. Urbanek,et al.  Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. , 2005, The Journal of clinical endocrinology and metabolism.

[123]  V. Padmanabhan,et al.  Polycystic Ovary Syndrome and Oocyte Developmental Competence , 2008, Obstetrical & gynecological survey.

[124]  M. Hersberger,et al.  Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. , 2009, Human reproduction.

[125]  P. Hardiman,et al.  Polycystic Ovary Syndrome and Endometrial Cancer , 2008, Seminars in reproductive medicine.

[126]  R. Legro,et al.  High prevalence of metabolic syndrome in first-degree male relatives of women with polycystic ovary syndrome is related to high rates of obesity. , 2009, The Journal of clinical endocrinology and metabolism.

[127]  E. Carmina,et al.  Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome , 2008, Journal of endocrinological investigation.

[128]  J. Marshall,et al.  Neuroendocrine aspects of polycystic ovary syndrome. , 1999, Endocrinology and metabolism clinics of North America.

[129]  G. Rini,et al.  Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. , 2005, The Journal of clinical endocrinology and metabolism.

[130]  E. Diamanti-Kandarakis,et al.  Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. , 2004, The Journal of clinical endocrinology and metabolism.

[131]  M. Maliqueo,et al.  Metabolic parameters in cord blood of newborns of women with polycystic ovary syndrome. , 2009, Fertility and sterility.

[132]  角田 明良,et al.  結腸癌術後の早期離床・早期経口摂取に関するProspective Randomized Trial , 2002 .

[133]  D. Abbott,et al.  Early origins of polycystic ovary syndrome. , 2005, Reproduction, fertility, and development.

[134]  D. Driscoll,et al.  Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[135]  H. Raff,et al.  Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. , 2007, The Journal of clinical endocrinology and metabolism.

[136]  M. Frye,et al.  Longitudinal evaluation of reproductive function in women treated for bipolar disorder. , 2005, Journal of affective disorders.

[137]  Polycystic ovaries and associated clinical and biochemical features in young women , 1999, Clinical endocrinology.

[138]  J. Marshall,et al.  Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenemic adolescent girls. , 2005, The Journal of clinical endocrinology and metabolism.

[139]  R. Norman,et al.  The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. , 2010, Human reproduction.

[140]  A. Kunselman,et al.  Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. , 2005, The Journal of clinical endocrinology and metabolism.

[141]  R. Azziz,et al.  Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. , 1999, Fertility and sterility.

[142]  A. Lucky,et al.  Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome. , 1990, Fertility and sterility.

[143]  F. Orio,et al.  Endothelial dysfunction in PCOS: role of obesity and adipose hormones. , 2006, The American journal of medicine.

[144]  A. Kunselman,et al.  Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. , 2001, The American journal of medicine.

[145]  J. Visser,et al.  Anti-Müllerian hormone: a new marker for ovarian function. , 2006, Reproduction.

[146]  S. Killick,et al.  Ultrasound diagnosis of polycystic ovaries in women who have no symptoms of polycystic ovary syndrome is not associated with subfecundity or subfertility. , 2003, Fertility and sterility.

[147]  T. Key,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study* , 2022 .

[148]  A. Marolt [Facts and hypotheses]. , 1953, Schweizerische Monatsschrift fur Zahnheilkunde = Revue mensuelle suisse d'odonto-stomatologie.

[149]  D. Abbott,et al.  Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? , 2005, Human reproduction update.

[150]  D. Ehrmann,et al.  Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. , 2006, The Journal of clinical endocrinology and metabolism.

[151]  F. Orio,et al.  Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. , 2009, Endocrine reviews.

[152]  S. Weitsman,et al.  Aromatase mRNA expression in individual follicles from polycystic ovaries. , 1998, Molecular human reproduction.

[153]  V. Padmanabhan,et al.  Prenatal testosterone excess programs reproductive and metabolic dysfunction in the female , 2006, Molecular and Cellular Endocrinology.

[154]  D. Seifer,et al.  Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. , 2007, Fertility and sterility.

[155]  R. Azziz,et al.  Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. , 2005, Fertility and sterility.

[156]  H. S. Davis,et al.  A Controlled Study , 1966 .

[157]  B. Carlsson,et al.  Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. , 1993, Fertility and sterility.

[158]  W. Crowley,et al.  Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome , 1998, Journal of endocrinological investigation.

[159]  K. Højlund,et al.  Impaired Insulin-Stimulated Phosphorylation of Akt and AS160 in Skeletal Muscle of Women With Polycystic Ovary Syndrome Is Reversed by Pioglitazone Treatment , 2008, Diabetes.

[160]  A. Vidal-Puig,et al.  Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective. , 2010, Biochimica et biophysica acta.

[161]  K. Sengoku,et al.  The chromosomal normality of unfertilized oocytes from patients with polycystic ovarian syndrome. , 1997, Human reproduction.

[162]  M. Hongo,et al.  Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. , 2000, Metabolism: clinical and experimental.

[163]  A. Gougeon Regulation of ovarian follicular development in primates: facts and hypotheses. , 1996, Endocrine reviews.

[164]  A. Balen,et al.  Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? , 2002, Clinical endocrinology.

[165]  A. Kunselman,et al.  Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. , 2002, The Journal of clinical endocrinology and metabolism.

[166]  A. Badawy,et al.  Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial. , 2009, Fertility and sterility.

[167]  R. Azziz,et al.  Impact of obesity on the risk for polycystic ovary syndrome. , 2008, The Journal of clinical endocrinology and metabolism.

[168]  M. Goodarzi Looking for polycystic ovary syndrome genes: rational and best strategy. , 2008, Seminars in reproductive medicine.

[169]  Mark I McCarthy,et al.  Mechanisms of Disease: genetic insights into the etiology of type 2 diabetes and obesity , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[170]  G. Di Fede,et al.  Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. , 2007, The Journal of clinical endocrinology and metabolism.

[171]  J. Adams,et al.  Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. , 2006, The Journal of clinical endocrinology and metabolism.

[172]  Family-based analysis of candidate genes for polycystic ovary syndrome. , 2010, The Journal of clinical endocrinology and metabolism.

[173]  C. Simón,et al.  Oocyte quality in polycystic ovaries revisited: Identification of a particular subgroup of women , 1997, Journal of Assisted Reproduction and Genetics.

[174]  Técia Maria do Oliveira Maranhão,et al.  Irregularidade do ciclo menstrual no menacme como marcador para fatores de risco cardiovasculares na pós-menopausa , 2006 .

[175]  E. Diamanti-Kandarakis,et al.  A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. , 1999, The Journal of clinical endocrinology and metabolism.

[176]  D. Boomsma,et al.  0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(6):2100–2104 Printed in U.S.A. Copyright © 2006 by The Endocrine Society doi: 10.1210/jc.2005-1494 Heritability of Polycystic Ovary Syndrome in a Dutch Twin-Family Study , 2022 .

[177]  M. Muggeo,et al.  Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. , 2000, The Journal of clinical endocrinology and metabolism.

[178]  F. de Zegher,et al.  Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. , 1998, The Journal of clinical endocrinology and metabolism.

[179]  S. Bhasin,et al.  Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. , 2009, The Journal of clinical endocrinology and metabolism.

[180]  S. Agarwal,et al.  A mechanism for the suppression of estrogen production in polycystic ovary syndrome. , 1996, The Journal of clinical endocrinology and metabolism.

[181]  L. Levitsky,et al.  Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. , 1994, The Journal of clinical endocrinology and metabolism.

[182]  S. Caprio,et al.  Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. , 2007, The Journal of clinical endocrinology and metabolism.

[183]  E. Diamanti-Kandarakis,et al.  Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. , 2001, The Journal of clinical endocrinology and metabolism.

[184]  D. Ferriman,et al.  THE INHERITANCE OF POLYCYSTIC OVARIAN DISEASE AND A POSSIBLE RELATIONSHIP TO PREMATURE BALDING , 1979, Clinical endocrinology.

[185]  Ximena Duque,et al.  Prevalence of Polycystic Ovary Syndrome and Related Disorders in Mexican Women , 2010, Gynecologic and Obstetric Investigation.

[186]  K. Chad,et al.  Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. , 2006, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[187]  Maja O’Connor LONGITUDINAL STUDY , 2013 .

[188]  F. Booth,et al.  Eating, exercise, and "thrifty" genotypes: connecting the dots toward an evolutionary understanding of modern chronic diseases. , 2004, Journal of applied physiology.

[189]  D. Ehrmann,et al.  Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[190]  V. Myllylä,et al.  Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. , 1994, The New England journal of medicine.

[191]  D. Dewailly,et al.  Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. , 2006, The Journal of clinical endocrinology and metabolism.

[192]  D. Panidis,et al.  Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS. , 2006, European journal of endocrinology.

[193]  R. Azziz,et al.  Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. , 2010, Fertility and sterility.

[194]  L. Kuller,et al.  Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. , 1996, American journal of obstetrics and gynecology.

[195]  J. Olefsky,et al.  Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. , 1992, The Journal of clinical endocrinology and metabolism.

[196]  D. Rosenbaum,et al.  Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. , 1993, The American journal of physiology.

[197]  F. Greenway,et al.  An Endocrine Society Clinical Practice Guideline Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: , 2010 .

[198]  J. Ruderman Faculty Opinions recommendation of The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function in vivo and induces insulin resistance. , 2006 .

[199]  R. Wing,et al.  Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. , 1994, Fertility and sterility.

[200]  S. Franks,et al.  Insulin action in the normal and polycystic ovary. , 1999, Endocrinology and metabolism clinics of North America.

[201]  D. Schoenfeld,et al.  Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. , 1997, The Journal of clinical endocrinology and metabolism.

[202]  R. Hart,et al.  Circulating maternal testosterone concentrations at 18 weeks of gestation predict circulating levels of antimüllerian hormone in adolescence: a prospective cohort study. , 2010, Fertility and sterility.

[203]  L. Moran,et al.  Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. , 2010, Human reproduction update.

[204]  V. Meyer-Rochow,et al.  Insulin Resistance and Depressive Symptoms in Young Adult Males: Findings From Finnish Military Conscripts , 2007, Psychosomatic medicine.

[205]  V. Padmanabhan,et al.  Endocrine Antecedents of Polycystic Ovary Syndrome in Fetal and Infant Prenatally Androgenized Female Rhesus Monkeys1 , 2008, Biology of reproduction.

[206]  M. Eijkemans,et al.  A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. , 2006, Human reproduction update.

[207]  R. Lobo,et al.  Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. , 2004, Fertility and sterility.

[208]  J. Nestler Metformin in the treatment of infertility in polycystic ovarian syndrome: an alternative perspective. , 2008, Fertility and sterility.

[209]  B. Fauser,et al.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). , 2004, Human reproduction.

[210]  B. V. Van Voorhis,et al.  Increased risk of depressive disorders in women with polycystic ovary syndrome. , 2007, Fertility and sterility.

[211]  T. Ciaraldi,et al.  Molecular defects of insulin action in the polycystic ovary syndrome: possible tissue specificity. , 2000, Journal of pediatric endocrinology & metabolism : JPEM.

[212]  T. Gurgan,et al.  Pregnancy in infertile PCOD patients. Complications and outcome. , 1997, The Journal of reproductive medicine.

[213]  H. Picton,et al.  South Asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts. , 2007, European journal of obstetrics, gynecology, and reproductive biology.

[214]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[215]  H. Escobar-Morreale,et al.  Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. , 2007, Human reproduction.

[216]  S. Weerakiet,et al.  Prevalence of gestational diabetes mellitus and pregnancy outcomes in Asian women with polycystic ovary syndrome , 2004, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[217]  F. V. van Leeuwen,et al.  Birth weight and age at menarche in patients with polycystic ovary syndrome or diminished ovarian reserve, in a retrospective cohort. , 2003, Human reproduction.

[218]  R. Legro,et al.  Bone mineral density and body composition in lean women with polycystic ovary syndrome. , 1999, Fertility and sterility.

[219]  S. Franks,et al.  Fertilization and early embryology: Normal development and metabolic activity of preimplantation embryos in vitro from patients with polycystic ovaries , 1995 .

[220]  S L Wolf,et al.  An Alternative Perspective , 1999, Applied psychophysiology and biofeedback.

[221]  E. Barrett-Connor,et al.  Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease , 2007, Menopause.

[222]  R. Legro,et al.  Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. , 2003, Human reproduction.

[223]  D. Abbott,et al.  Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys , 2009, American journal of primatology.

[224]  J. Olefsky,et al.  Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. , 1997, The Journal of clinical endocrinology and metabolism.

[225]  R. Clayton,et al.  How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? , 1992, Clinical endocrinology.

[226]  A. Dokras,et al.  Screening Women With Polycystic Ovary Syndrome for Metabolic Syndrome , 2005, Obstetrics and gynecology.

[227]  L. Altshuler,et al.  Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. , 2003, Journal of affective disorders.

[228]  W. Dodson,et al.  Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives. , 2010, The Journal of clinical endocrinology and metabolism.

[229]  R. Rosenfield Clinical review: Identifying children at risk for polycystic ovary syndrome. , 2007, The Journal of clinical endocrinology and metabolism.

[230]  A. Oberg,et al.  Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. , 2003, The Journal of clinical endocrinology and metabolism.

[231]  L. Giudice,et al.  Endocrine-disrupting chemicals: an Endocrine Society scientific statement. , 2009, Endocrine reviews.

[232]  R. Norman,et al.  Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. , 1998, Human reproduction.

[233]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[234]  A. Prentice,et al.  Type 2 diabetes, cardiovascular disease, and the evolutionary paradox of the polycystic ovary syndrome: A fertility first hypothesis , 2009, American journal of human biology : the official journal of the Human Biology Council.

[235]  N. Cox,et al.  Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. , 2001, The Journal of clinical endocrinology and metabolism.

[236]  M. Maliqueo,et al.  Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. , 2002, Human reproduction.

[237]  R. Norman,et al.  Insulin resistance increases the risk of spontaneous abortion after assisted reproduction technology treatment. , 2007, The Journal of clinical endocrinology and metabolism.

[238]  Paloma Alonso-Magdalena,et al.  The Estrogenic Effect of Bisphenol A Disrupts Pancreatic β-Cell Function In Vivo and Induces Insulin Resistance , 2005, Environmental health perspectives.

[239]  H. White,et al.  Association between Polycystic Ovaries and Extent of Coronary Artery Disease in Women Having Cardiac Catheterization , 1997, Annals of Internal Medicine.